As the COVID-19 pandemic continues to spread across the United States it is imperative that we implement
technologies to screen large swaths of the population for the presence of antibodies to SARS-CoV-2.
Serological surveillance not only affords a measure of virus exposure within a community at large but also
provides information necessary to predict outbreak dynamics. Furthermore, as our understanding of how
humoral factors contribute to controlling (and possibly exacerbating) COVID-19, it will be essential to have
methods in place to measure the “quantity” and “quality” of antibodies associated with both natural SARS-CoV-
2 exposure and candidate SARS-CoV-2 vaccines. This U01 proposal seeks to advance the use of dried blood
spots (DBS) in conjunction with a Luminex-based microsphere immunoassay (MIA) to enable high-throughput
(HT) population-wide serological surveillance for SARS-CoV-2. Specifically, the proposal will expand the HT-
DBS assay to capture the breadth and complexity of SARS-CoV-2 antibody responses following natural
infection, and develop a high-throughput competitive immunoassay (CIA) as a surrogate measure of SARS-
CoV-2 neutralizing antibody titers in DBS. The proposed platform technologies to be developed at the
Wadsworth Center will contribute directly to NCI’s mission to “… develop, validate, improve and implement
serological testing and associated technologies…” to address the COVID-19 pandemic.